Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

G&D, IAVI and GMI partner to develop new HIV/AIDS vaccine

The International AIDS Vaccine Initiative (IAVI), GlycoMimetics, Inc. (GMI), and Glycosensors and Diagnostics, LLC (G&D) today announced a collaboration to develop an AIDS vaccine using novel compounds that mimic carbohydrates, called glycomimetics.

10 May 2012

Inovio first quarter total revenue decreases to $1.7 million

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2012.

10 May 2012

iBio receives U.S. patent for iBioModulator platform

iBio, Inc. today announced issuance of a US patent covering compositions of matter and methods of use of modified lichenase B polypeptides comprising the Company's iBioModulator platform.

9 May 2012

Scientists make important discovery about internal programming of B cells

Scientists at The Scripps Research Institute have made an important discovery about the internal programming of B cells, the immune cells that make antibodies against infections. The finding opens the way for the development of vaccines that can work more efficiently and hints at therapies for conditions in which B cells cause harm—such as the autoimmune disease lupus erythymatosus, severe allergies, and B-cell lymphomas.

8 May 2012

Intellect Neurosciences announces two new programs in Alzheimer's disease development pipeline

Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, today announced two new programs in its Alzheimer's disease development pipeline. The new programs are based on two antibodies that target early neurotoxic forms of tau protein, which Intellect intends to develop for therapeutic and diagnostic uses.

7 May 2012

Positive long-term outcome data for chronic ITP patients treated with rituxamab

A new analysis concludes that rituximab, a drug commonly used to treat blood cancers, leads to treatment responses lasting at least five years in approximately one quarter of patients with low platelet counts and a risk of bleeding due to chronic immune thrombocytopenic purpura (ITP).

7 May 2012

NovaDigm reports positive data from Phase 1 NDV-3 vaccine program

NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced the presentation of positive data for its NDV-3 vaccine program in a second Phase 1 study.

7 May 2012

Data from Idera IMO-8400 preclinical studies for SLE and psoriasis presented at AAI meeting

Idera Pharmaceuticals, Inc. today announced data from preclinical studies of IMO-8400, demonstrating a novel mechanism of action that may be applicable to the treatment of systemic lupus erythematosus (SLE) and psoriasis. IMO-8400 is an inhibitor of specific Toll-like receptors (TLRs).

7 May 2012

Ventana granted FDA clearance for Companion Algorithm p53 (DO-7) image analysis application

Ventana Medical Systems, Inc., a member of the Roche Group, received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the VENTANA Companion Algorithm p53 (DO-7) image analysis application using the VENTANA iScan Coreo Au scanner and VIRTUOSO software.

7 May 2012

Integral Molecular receives U.S. patent for methodology that generates Lipoparticles

Integral Molecular, a leader in membrane protein reagents and services, announces the issuance of a key patent protecting its methodology for generating Lipoparticles, which provide highly-concentrated membrane proteins in their native conformation for antibody and drug discovery applications focused on membrane protein targets such as G protein-coupled receptors (GPCRs), ion channels, and transporters.

4 May 2012

SC formulation of Genentech’s ACTEMRA shows promise against RA

Genentech, a member of the Roche Group, today announced that the SUMMACTA study met its primary endpoint, showing comparable efficacy (non-inferiority) of the subcutaneous (SC) formulation of ACTEMRA (tocilizumab) 162mg weekly compared to 8 mg/kg ACTEMRA intravenous (IV) formulation every four weeks.

3 May 2012

Biogen Idec first quarter revenues increase 7% to $1.3 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced its first quarter 2012 results.

2 May 2012

Topline, interim results from Celldex Phase 2b EMERGE study of CDX-011 for advanced breast cancer

Celldex Therapeutics, Inc. today announced that interim, topline results of the Phase 2b EMERGE study of CDX-011 in patients with advanced breast cancer will be presented in a webcast on May 23, 2012. Linda Vahdat, MD, Professor of Medicine, Chief of Solid Tumor Service and Director of the Breast Cancer Research Program at Weill Cornell Medical College and the lead investigator of the EMERGE study, will join Celldex on the webcast to discuss data from the study.

2 May 2012

Sanofi Pasteur announces new quadrivalent influenza vaccine Phase III pediatric data

Sanofi Pasteur, the vaccines division of Sanofi, announced today new Phase III data for its investigational quadrivalent influenza vaccine (QIV) in children 6 months through 8 years of age.

2 May 2012

Antibody that neutralizes enzyme Kallikrein 6 staves off MS

Researchers studying multiple sclerosis(MS) have long been looking for the specific molecules in the body that cause lesions in myelin, the fatty, insulating cells that sheathe the nerves.

30 Apr 2012

Researchers define structure of key part of human obesity receptor

Medical researchers at the University of Sheffield have defined the structure of a key part of the human obesity receptor- an essential factor in the regulation of body fat- which could help provide new treatments for the complications of obesity and anorexia.

27 Apr 2012

FDA issues Complete Response Letter to Amgen’s sBLA for XGEVA

Amgen today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for the supplemental Biologics License Application (sBLA) for XGEVA (denosumab) to treat men with castration-resistant prostate cancer (CRPC) at high risk of developing bone metastases.

27 Apr 2012

Leica receives FDA Pre-Market Approval for new HER2 IHC test

Leica Biosystems, a division of Leica Microsystems, announced that it has received Pre-Market Approval from the U.S. Food and Drug Administration for the Leica Bond Oracle HER2 IHC System with the Leica BOND-MAX, establishing their commitment to developing quality companion diagnostic products.

26 Apr 2012

Clinical and Translational Science Institute-Children's National awards pilot grant to GW researchers

GW researchers in the School of Medicine, Jeffrey M. Bethony, Ph.D., Associate Professor of Microbiology, Immunology, and Tropical Medicine and David Diemert, M.D., FRCP(C), Associate Research Professor of Microbiology, Immunology, and Tropical Medicine and Director of Clinical Trials for the Sabin Vaccine Institute's Product Development Partnership (PDP), have been awarded a Pilot Grant from the Clinical and Translational Science Institute-Children's National.

25 Apr 2012

Immunosignatures can yield reliable and highly stable diagnostic results

Identifying diseases at an early, presymptomatic stage may offer the best chance for establishing proper treatment and improving patient outcomes. A new technique known as immunosignaturing harnesses the human immune system as an early warning sentry-one acutely sensitive to changes in the body that may be harbingers of illness.

24 Apr 2012